Is There a Relationship between Androgenic Alopecia and Benign Prostatic Hyperplasia?
Androgenic alopecia as a physiologic process and benign prostatic hyperplasia (BPH) as a pathologic process in the older population are androgen-dependent processes influenced by 5-alpha reductase enzyme which converts testosterone to dihydrotestosterone. This cross sectional study was done to evaluate the relationship between androgenic alopecia and BPH. 150 men older than 50 years old, who presented to the free prostate screening clinic, were included. They were asked about urinary symptoms. PSA level, prostate volume with sonography and alopecia grading using Hamilton-Norwood classification (grade I to VII) were evaluated. Analysis was done by SPSS statistical method. 59.6% of men had mild alopecia (grade I, II, III), 34.1% had moderate alopecia (grade IV, V) and 6.3% had severe alopecia (grade VI, VII).The mean PSA level was 1.37 ± 1.48 ng/ml. The minimum PSA level was 0.1 ng/ml, and the maximum level was 6.8 ng/ml. The mean prostate volume was 37.85 ± 21.85cc. The minimum prostate size was 10 ml, and the maximum volume was 173 ml. The mean international prostate symptom score (IPSS) was 7.6 ± 6.11 with the minimum score 0 and the maximum score 27. However, no relationship between these parameters and androgenic alopecia was detected. This study showed that there is no relationship between androgenic alopecia, PSA level, IPSS, and prostate volume. Occurrence of alopecia in younger age and a positive family history correlated with a higher grade of alopecia.
Chen W, Yang CC, Chen GY, et al. Patients With a largeprostate show a higher prevalence of androgenic alopecia. Arch Dermatol Res 2004;296(6):245-9.
Habif TP, editor. Clinical dermatology, a color guide to diagnosis and therapy. 4th ed. London: Mosby Company; 2002: p. 310-5.
Veltri R, Rodrigez R. Molecular biology/endocrinology and physiology of the prostate. In: Wein AJ, Kavoussi LR, Novick AC, et al, editors. Campbell’s urology. 8th ed. Philadelphia. Saunders; 2003: p. 2749-843.
Carson C 3rd, Rittmaster R. The role of dihyrotestosterone in benign prostatic hyperplasia. Urology 2003;61(4 Suppl1):2-7.
Simpson NB, Cunliffe WJ. Disorders of hairs. In: Burns T, Breathnach S, Cox N, et al, editors. Rook’s textbook of dermatology. 7th ed. Oxford: Blackwell Publishing; 2004: 1-220.
Oh BR, Kim SJ, Moon JD, et al. Association of benign prostatic hyperplasia with male pattern baldness. Urology 1998;51(5):744-8.
Arias-Santiago S, Arrabal-Polo MA, Buendía-Eisman A, et al. Androgenetic alopecia as an early marker of benignprostatic hyperplasia. J Am Acad Dermatol 2012;66(3):401-8.
Kaplan SA. Re: Androgenetic alopecia as an early marker of benign prostatic hyperplasia. J Urol 2012;188(5):1846-7.
Faydaci G, Bilal E, Nece mettin P, et al. Baldness, benign prostate hyperplasia, prostate cancer and androgen level. Aging Male 2008;11(4):189-92.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.